Liver health may change how lung cancer drug works
NCT ID NCT05329623
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how the drug JDQ443 behaves in people with different levels of liver function. It included 33 adults with small cell lung cancer and mild, moderate, or severe liver problems, plus healthy volunteers. The goal was to measure drug levels in the blood to guide safe dosing for patients with liver issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Orlando Clinical Research Center
Orlando, Florida, 32809, United States
-
Texas Liver Institute
San Antonio, Texas, 78215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chemo-Immunotherapy duo outsmart tough lung cancer?
- Can head radiation stop lung cancer from spreading to the brain?
- New hope for tough lung cancer: drug plus radiation combo shows promise in early trial
- New hope for hard-to-treat cancers? experimental combo enters phase 2 trial
- New hope for tough lung cancer: early trial launches in china
- Laser and Light-Sensitive drug shrink lung tumors in early trial